



## Maze Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference

February 25, 2026

SOUTH SAN FRANCISCO, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced that Jason Coloma, Ph.D., chief executive officer of Maze Therapeutics, will present at the TD Cowen 46<sup>th</sup> Annual Health Care Conference on Wednesday, March 4, 2026 at 10:30 a.m. ET.

A live webcast of the event will be available in the Investors section of the Maze Therapeutics website at [www.mazetx.com](http://www.mazetx.com) and archived for 60 days following the presentation.

### About Maze Therapeutics

Maze Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel small molecule precision medicines for patients with kidney and metabolic diseases, including obesity. Guided by its Compass™ platform, Maze pursues genetically validated targets by integrating variant discovery and functionalization to discover and advance small molecule programs with first- or best-in-class potential. Maze's pipeline is led by MZE829, a dual-mechanism APOL1 inhibitor in Phase 2 development for APOL1-mediated kidney disease (AMKD), and MZE782, a SLC6A19 inhibitor advancing to Phase 2 with the potential to treat both phenylketonuria (PKU) and chronic kidney disease (CKD). Maze is headquartered in South San Francisco. For more information, please visit [mazetx.com](http://mazetx.com), or follow the company on [LinkedIn](#) and [X](#).

### IR/Corporate Contact:

Amy Bachrodt, Maze Therapeutics  
[abachrodt@mazetx.com](mailto:abachrodt@mazetx.com)

### Media Contact:

Amanda Lazaro, 1AB Media  
[Amanda@1ABMedia.com](mailto:Amanda@1ABMedia.com)